Waverley Pharma Inc. WAVE.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · waverleypharma.com
Canadian biopharmaceutical company focused on research, development, and commercialization of oncology therapeutics, primarily PARP-1 inhibitors for cancer treatment. Also manages a licensed portfolio of cancer medications including Capecitabine and Temozolomide, with commercial launches in the United Kingdom and Germany. Operates a retail pharmacy in the United States acquired in 2024 to generate near-term revenue.
Key ratios
FreeCashFlowOnSale TTM -0.31
FreeCashFlowOnSale 2024 -0.86
FreeCashFlowOnSale 2023 -2.48
FreeCashFlowOnSale 2022 -0.19
NetIncomeMargin TTM -0.24
NetIncomeMargin 2024 -1.99
NetIncomeMargin 2022 -0.53
ReturnOnAssets TTM -0.12
ReturnOnAssets 2024 -0.36
ReturnOnAssets 2023 -0.44
ReturnOnAssets 2022 -0.18
ReturnOnEquity 2022 -0.46
TotalRevenueYoYGrowth TTM 20.16
TotalRevenueYoYGrowth 2024 0.15
TotalRevenueYoYGrowth 2023 -0.67
TotalRevenueYoYGrowth 2022 -0.29
Recent news
Waverley Pharma Announces Chief Financial Officer Change
2026-07-17 · CNW